We thank Dr. Ajay Kumar Mishra and his colleagues for their attention to our review.(1, 2) We strongly agree with them that it is inappropriate for COVID‐19 patients to discontinue ACEIs /ARBs without weighing up the pros and cons.(3, 4) Whether the RAAS inhibitors may affect the prognosis of COVID‐19 patients still needs more clinical trials to confirm. This article is protected by copyright. All rights reserved.